Review: Beyond KRAS: Perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer

Therapeutic Advances in Medical Oncology

Volumn 1, Issue 3, 2009, Pages 167-181

  Loupakis, Fotios ^a   Falcone, Alfredo ^a   Cremolini, Chiara ^b   Stasi, Irene ^b   Salvatore, Lisa ^b   Fontanini, Gabriella ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

cetuximab; colorectal cancer; epidermal growth factor receptor; panitumumab; predictive factors

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; VANDETANIB; VASCULOTROPIN;

CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DRUG EFFICACY; GENE MUTATION; GENOTYPE; HUMAN; KIRSTEN SARCOMA ONCOVIRUS; METASTASIS; METASTATIC COLORECTAL CANCER; MONOTHERAPY; NONHUMAN; PATIENT SELECTION; PHARMACOGENOMICS; PHENOTYPE; POST HOC ANALYSIS; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; TREATMENT RESPONSE; VIRUS ONCOGENE; WILD TYPE;

EID: 77953367684     PISSN: 17588340     EISSN: None     Source Type: Journal    
DOI: 10.1177/1758834009348984     Document Type: Review

References (88)

1. Albitar, M., Yeh, C. and Ma, W. (2009) K-Ras mutations and cetuximab in colorectal cancer. N Engl J Med 360: 834.
2. Allegra, C.J., Jessup, J.M., Somerfield, M.R., Hamilton, S.R., Hammond, E.H., Hayes, D.F. et al. (2009) American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27: 2091-2096.
3. Amado, R.G., Wolf, M., Peeters, M., van Cutsem, E., Siena, S., Freeman, D.J. et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634.
4. Amador, M., Oppenheimer, D., Perea, S. and Maitra, A. ( 2004) An epidermal growth factor receptor intron 1 polymoprhism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 64: 9139-9143.
5. Andreyev, H.J., Norman, A.R., Cunningham, D., Oates, J., Dix, B.R., Iacopetta, B.J. et al. (2001) Kirsten RAS mutations in patients with colorectal cancer: the ‘Rascal II’ study. Br J Cancer 85: 692-696.
6. Anon. (2008) Committee for medicinal products for human use post-authorisation summary of positive opinion for Erbitux. Available at: http://www.emea.europa.eu/pdfs/human/opinion/Erbitux_28040208en.pdf.
7. Atkins, D., Reiffen, K.A., Tegtmeier, C.L., Winther, H., Bonato, M.S. and Storkel, S. ( 2004) Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 52: 893-901.
8. Benavente, S., Huang, S., Armstrong, E.A., Chi, A., Hsu, K.T., Wheeler, D.L. et al. (2009) Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clin Cancer Res 15: 1585-1592.
9. Benvenuti, S., Sartore-Bianchi, A., Di Nicolantonio, F., Zanon, C., Moroni, M., Veronese, S. et al. (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67: 2643-2648.
10. Bianco, R., Garofalo, S., Rosa, R., Damiano, V., Gelardi, T., Daniele, G. et al. (2008) Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 98: 923-930.
11. Bianco, R., Rosa, R., Damiano, V., Daniele, G., Gelardi, T., Garofalo, S. et al. (2008) Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. Clin Cancer Res 14: 5069-5080.
12. Bibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F. et al. (2009) Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 27: 1122-1129.
13. Biscardi, J.S., Maa, M.C., Tice, D.A., Cox, M.E., Leu, T.H. and Parsons, S.J. ( 1999) C-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr 845 and Tyr 1101 is associated with modulation of receptor function. J Biol Chem 274: 8335-8343.
14. Bokemeyer, C., Bondarenko, I., Makhson, A., Hartmann, J.T., Aparicio, J., de Braud, F. et al. (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27: 663-671.
15. Bruns, C.J., Solorzano, C.C., Harbison, M.T., Ozawa, S., Tsan, R., Fan, D. et al. (2000) Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60: 2926-2935.
16. Buhrman, G., Wink, G. and Mattos, C. ( 2007) Transformation efficiency of RASq 61 mutants linked to structural features of the switch regions in the presence of RAF. Structure 15: 1618-1629.
17. Chakravarti, A., Loeffler, J.S. and Dyson, N.J. ( 2002) Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62: 200-207.
18. Chung, K.Y., Shia, J., Kemeny, N.E., Shah, M., Schwartz, G.K., Tse, A. et al. (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23: 1803-1810.
19. Ciardiello, F., Bianco, R., Caputo, R., Damiano, V., Troiani, T., Melisi, D. et al. (2004) Antitumor activity of Zd6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 10: 784-793.
20. Ciardiello, F., Bianco, R., Damiano, V., Fontanini, G., Caputo, R., Pomatico, G. et al. (2000) Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C 225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human geo colon cancer cells. Clin Cancer Res 6: 3739-3747.
21. Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A. et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345.
22. de Roock, W., Lambrechts, D. and Tejpar, S. (2009) K-RAS mutations and cetuximab in colorectal cancer. N Engl J Med 360: 834.
23. de Roock, W., Piessevaux, H., de Schutter, J., Janssens, M., de Hertogh, G., Personeni, N. et al. (2007) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19: 508-515.
24. Di Fiore, F., Blanchard, F., Charbonnier, F., Le Pessot, F., Lamy, A., Galais, M.P. et al. (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 96: 1166-1169.
25. Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P. et al. (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26: 5705-5712.
26. Edkins, S., O’Meara, S., Parker, A., Stevens, C., Reis, M., Jones, S. et al. (2006) Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther 5: 928-932.
27. Faul, M.M., Gillig, J.R., Jirousek, M.R., Ballas, L.M., Schotten, T., Kahl, A. et al. (2003) Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta. Bioorg Med Chem Lett 13: 1857-1859.
28. Frattini, M., Saletti, P., Romagnani, E., Martin, V., Molinari, F., Ghisletta, M. et al. (2007) PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97: 1139-1145.
29. Garm Spindler, K.L., Pallisgaard, N., Rasmussen, A.A., Lindebjerg, J., Andersen, R.F., Cruger, D. et al. (2009) The importance of KRAS mutations and EGF61A > G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann Oncol 20: 879-884.
30. Gebhardt, F., Zanker, K.S. and Brandt, B. ( 1999) Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 274: 13176-13180.
31. Gelardi, T., Caputo, R., Damiano, V., Daniele, G., Pepe, S., Ciardiello, F. et al. (2008) Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 99: 473-480.
32. Goel, A., Arnold, C., Niedzwiecki, D., Care thers, J., Dowell, J., Wasserman, L. et al. (2004) Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res 64: 3014-3021.
33. Graziano, F., Ruzzo, A., Loupakis, F., Canestrari, E., Santini, D., Catalano, V. et al. (2008) Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J Clin Oncol 26: 1427-1434.
34. Hebbar, M., Wacrenier, A., Desauw, C., Romano, O., Cattan, S., Triboulet, J.P. et al. (2006) Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs 17: 855-857.
35. Hecht, J.R., Mitchell, E., Chidiac, T., Scroggin, C., Hagenstad, C., Spigel, D. et al. (2009) A randomized phase IIIb trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27: 672-680.
36. Herbst, R.S. and Shin, D.M. ( 2002) Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94: 1593-1611.
37. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W. et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
38. Jhawer, M., Goel, S., Wilson, A.J., Montagna, C., Ling, Y.H., Byun, D.S. et al. (2008) PIK3ca mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68: 1953-1961.
39. Jimeno, A., Messersmith, W.A., Hirsch, F.R., Franklin, W.A. and Eckhardt, S.G. (2009) KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 27: 1130-1136.
40. Jonker, D.J., O’Callaghan, C.J., Karapetis, C.S., Zalcberg, J.R., Tu, D., Au, H.J. et al. (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040-2048.
41. Karapetis, C.S., Khambata-Ford, S., Jonker, D.J., O’Callaghan, C.J., Tu, D., Tebbutt, N.C. et al. (2008) K-RAS mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765.
42. Kawaguchi, Y., Kono, K., Mimura, K., Sugai, H., Akaike, H. and Fujii, H. ( 2007) Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 120: 781-787.
43. Khambata-Ford, S., Garrett, C.R., Meropol, N.J., Basik, M., Harbison, C.T., Wu, S. et al. (2007) Expression of epiregulin and amphiregulin and K-RAS mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25: 3230-3237.
44. Lievre, A., Bachet, J.B., Boige, V., Cayre, A., Le Corre, D., Buc, E. et al. (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374-379.
45. Lievre, A., Bachet, J.B., Le Corre, D., Boige, V., Landi, B., Emile, J.F. et al. (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995.
46. Linardou, H., Dahabreh, I., Kanaloupiti, D., Siannis, F., Bafaloukos, D., Kosmidis, P. et al. (2008) Assessment of somatic K-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9: 962-972.
47. Loupakis, F., Pollina, L., Stasi, I., Ruzzo, A., Scartozzi, M., Santini, D. et al. (2009) PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27: 2622-2629.
48. Lu, K., Mcguire, J.J., Slocum, H.K. and Rustum, Y.M. ( 1997) Mechanisms of acquired resistance to modulation of 5-fluorouracil by leucovorin in HCT-8 human ileocecal carcinoma cells. Biochem Pharmacol 53: 689-696.
49. Lurje, G., Nagashima, F., Zhang, W., Yang, D., Chang, H.M., Gordon, M.A. et al. (2008) Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-RAS in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res 14: 7884-7895.
50. Moriai, T., Kobrin, M.S., Hope, C., Speck, L. and Korc, M. ( 1994) A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling. Proc Natl Acad Sci U S A 91: 10217-10221.
51. Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F. et al. (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6: 279-286.
52. Niwa, R., Hatanaka, S., Shoji-Hosaka, E., Sakurada, M., Kobayashi, Y., Uehara, A. et al. (2004) Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IGGL is independent of FcgammarIIIa functional polymorphism. Clin Cancer Res 10: 6248-6255.
53. Oden-Gangloff, A., Di Fiore, F., Bibeau, F., Lamy, A., Bougeard, G., Charbonnier, F. et al. (2009) Tp 53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. Br J Cancer 100: 1330-1335.
54. Ogino, S., Kawasaki, T., Brahmandam, M., Yan, L., Cantor, M., Namgyal, C. et al. (2005) Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn 7: 413-421.
55. Ogino, S., Nosho, K., Kirkner, G.J., Shima, K., Irahara, N., Kure, S. et al. (2009) PIK3ca mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 27: 1477-1484.
56. Perrone, F., Lampis, A., Orsenigo, M., Di Bartolomeo, M., Gevorgyan, A., Losa, M. et al. (2008) PI3KCA/ PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 20: 84-90.
57. Perrotte, P., Matsumoto, T., Inoue, K., Kuniyasu, H., Eve, B.Y., Hicklin, D.J. et al. (1999) Anti-epidermal growth factor receptor antibody C 225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5: 257-265.
58. Petit, A.M., Rak, J., Hung, M.C., Rockwell, P., Goldstein, N., Fendly, B. et al. (1997) Neutralizing antibodies against epidermal growth factor and ERBB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151: 1523-1530.
59. Piette, J., Neel, H. and Marechal, V. ( 1997) MDM2: keeping P 53 under control. Oncogene 15: 1001-1010.
60. Pintilie, M., Iakovlev, V., Fyles, A., Hedley, D., Milosevic, M. and Hill, R.P. (2009) Heterogeneity and power in clinical biomarker studies. J Clin Oncol 27: 1517-1521.
61. Prenen, H., de Schutter, J., Jacobs, B., de Roock, W., Biesmans, B., Claes, B. et al. (2009) PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 15: 3184-3188.
62. Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K.W., Vogelstein, B. and Velculescu, V.E. ( 2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418: 934.
63. Rodriguez-Viciana, P., Tetsu, O., Oda, K., Okada, J., Rauen, K. and Mccormick, F. ( 2005) Cancer targets in the RAS pathway. Cold Spring Harb Symp Quant Biol 70: 461-467.
64. Saltz, L.B., Lenz, H.J., Kindler, H.L., Hochster, H.S., Wadler, S., Hoff, P.M. et al. (2007) Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the bond-2 study. J Clin Oncol 25: 4557-4561.
65. Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S. et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
66. Sartore-Bianchi, A., Martini, M., Molinari, F., Veronese, S., Nichelatti, M., Artale, S. et al. (2009) PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69: 1851-1857.
67. Sartore-Bianchi, A., Moroni, M., Veronese, S., Carnaghi, C., Bajetta, E., Luppi, G. et al. (2007) Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 25: 3238-3245.
68. Scartozzi, M., Bearzi, I., Berardi, R., Mandolesi, A., Fabris, G. and Cascinu, S. ( 2004) Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 22: 4772-4778.
69. Shahbazi, M., Pravica, V., Nasreen, N., Fakhoury, H., Fryer, A.A., Strange, R.C. et al. (2002) Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 359: 397-401.
70. Simi, L., Pratesi, N., Vignoli, M., Sestini, R., Cianchi, F., Valanzano, R. et al. (2008) High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol 130: 247-253.
71. Sobrero, A.F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y.A., Lutz, M.P. et al. (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26: 2311-2319.
72. Tejpar, S., de Roock, W., Biesmans, B., de Schutter, J., Piessevaux, H., Humblet, Y. et al. (2008) High amphiregulin and epiregulin expression in KRAS wild type colorectal primaries predicts response and survival benefit after treatment with cetuximab and irinotecan for metastatic disease. Proceedings 2008 Gastrointestinal Cancers Symposium Abstr. 411.
73. Tice, D.A., Biscardi, J.S., Nickles, A.L. and Parsons, S.J. ( 1999) Mechanism of biological synergy between cellular SRC and epidermal growth factor receptor. Proc Natl Acad Sci U S A 96: 1415-1420.
74. Tol, J., Dijkstra, J.R., Vink-Borger, M.E., Nagtegaal, I.D., Punt, C.J., van Krieken, J.H. et al. (2009 b) High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell Mol Med: in press.
75. Tol, J., Koopman, M., Cats, A., Rodenburg, C.J., Creemers, G.J., Schrama, J.G. et al. (2009 a) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360: 563-572.
76. van Cutsem, E., Kohne, C.H., Hitre, E., Zaluski, J., Chang Chien, C.R., Makhson, A. et al. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417.
77. van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B. et al. (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658-1664.
78. van Heek, N.T., Clayton, S.J., Sturm, P.D., Walker, J., Gouma, D.J., Noorduyn, L.A. et al. (2005) Comparison of the novel quantitative arms assay and an enriched PCR-ASO assay for K-RAS mutations with conventional cytology on endobiliary brush cytology from 312 consecutive extrahepatic biliary stenoses. J Clin Pathol 58: 1315-1320.
79. van Krieken, J.H., Jung, A., Kirchner, T., Carneiro, F., Seruca, R., Bosman, F.T. et al. (2009) KRAS mutation testing for predicting response to Anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 454: 233-235.
80. van Royen-Kerkhof, A., Sanders, E.A., Wijngaarden, S., van Roon, J.A., Voorhorst-Ogink, M. et al. (2004) Flow cytometric determination of FcgammarIIa (Cd32) polymorphism. J Immunol Methods 294: 135-144.
81. Viloria-Petit, A., Crombet, T., Jothy, S., Hicklin, D., Bohlen, P., Schlaeppi, J.M. et al. (2001) Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 61: 5090-5101.
82. Wan, P.T., Garnett, M.J., Roe, S.M., Lee, S., Niculescu-Duvaz, D., Good, V.M. et al. (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116: 855-867.
83. Westra, J.L., Schaapveld, M., Hollema, H., de Boer, J.P., Kraak, M.M., de Jong, D. et al. (2005) Determination of Tp 53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol 23: 5635-5643.
84. Wheeler, D.L., Huang, S., Kruser, T.J., Nechrebecki, M.M., Armstrong, E.A., Benavente, S. et al. (2008) Mechanisms of acquired resistance to cetuximab: role of HER (ERBB) family members. Oncogene 27: 3944-3956.
85. Wheeler, D.L., Iida, M., Kruser, T.J., Nechrebecki, M.M., Dunn, E.F., Armstrong, E.A. et al. (2009) Epidermal growth factor receptor cooperates with SRC family kinases in acquired resistance to cetuximab. Cancer Biol Ther 8: 696-703.
86. Xu, K. and Shu, H.K. ( 2007) EGFR activation results in enhanced cyclooxygenase-2 expression through P 38 mitogen-activated protein kinase-dependent activation of the Sp1/Sp3 transcription factors in human gliomas. Cancer Res 67: 6121-6129.
87. Zhang, W., Gordon, M., Schultheis, A.M., Yang, D.Y., Nagashima, F., Azuma, M. et al. (2007) Fcgr2a and Fcgr3a polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 25: 3712-3718.
88. Zhou, X.P., Loukola, A., Salovaara, R., Nystrom-Lahti, M., Peltomaki, P., De La Chapelle, A. et al. (2002) PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol 161: 439-447.